In those with high GV due mainly to hypoglycaemia, the type of agents used need to be reviewed, such as replacing a sulphonylurea with other agents in T2D, altering insulin doses, types or regimens in insulin‐treated diabetes, or replacing insulin injections with pumps or hybrid closed loop systems in T1D. This evidence concerns the gene INS and type 1 diabetes mellitus.